CORVUS PHARMACEUTICALS INC
CRVSNASDAQ🏆 #1815 by market capEarnings Nov 3US Equity
$14.73▲ $1.06 (+7.21%)
Live1h—
24h▲ 7.2%
7d▲ 5.7%
14d▲ 13.0%
30d▲ 0.2%
1y▲ 226.6%
🏦Market Cap
$1.24B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
57
Weak
📊
Analyst Ratings
Price
$14.73
Total
13
Raised
1
Lowered
0
Avg PT
$27.56
| Institution | Action | Rating | Date |
|---|---|---|---|
Oppenheimer | Reiterated | Outperform | 2026-03-13 |
Jefferies | Reiterated | Buy | 2026-01-22 |
Barclays | Reiterated | Overweight | 2026-01-21 |
HC Wainwright & Co. | Reiterated | Buy | 2026-01-20 |
Mizuho | Reiterated | Outperform | 2025-05-20 |
Ladenburg Thalmann | Reiterated | Buy | 2024-09-16 |
Cantor Fitzgerald | Reiterated | Overweight | 2023-09-07 |
Wedbush | Reiterated | Outperform | 2020-03-13 |
H.C. Wainwright | Reiterated | Buy | 2020-03-10 |
Roth Capital | Reiterated | Buy | 2019-05-29 |
Credit Suisse | Upgraded | Underperform → Neutral | 2017-08-24 |
BTIG Research | Reiterated | Buy | 2016-04-19 |
Guggenheim | Reiterated | Buy | 2016-04-18 |
One row per institution, most recent rating